查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1621347

带状疱疹疫苗市场：按产品、类型和分销管道 - 2025-2030 年全球预测

Shingles Vaccine Market by Product (SkyZoster, Zostavax, Shingrix), Type (Live Attenuated Vaccine, Recombinant Vaccine), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

带状疱疹疫苗市场 2023 年估值为 17.3 亿美元，预计 2024 年将达到 18.7 亿美元，复合年增长率为 8.11%，到 2030 年将达到 29.9 亿美元。

全球带状疱疹疫苗市场的定义特别着重于预防 50 岁及以上族群的带状疱疹感染。带状疱疹是由水痘带状疱疹病毒（水痘）重新运作引起的，需要接种疫苗以减少带状疱疹后遗症神经痛等严重併发症。这个市场是由老年人口的增加、疾病意识的增强以及疫苗技术的进步所推动的。主要应用包括老年保健和免疫力缺乏患者管理。最终用户采用范围包括医院、诊所和专业医疗中心。成长要素包括积极的政府措施、有利的报销政策和医疗保健支出的增加。机会存在于疫苗接种率低的新兴市场、增加疫苗库存目标的机会以及创新交付方法的伙伴关係。目前的建议是扩大教育计画以提高吸收率，并采取针对高风险族群的行销策略。然而，高昂的製造成本、较高的监管障碍以及对疫苗安全性的怀疑正在阻碍市场的快速渗透。此外，还存在疫苗分配中的物流问题、疫苗犹豫的影响以及在医疗保健产品方面享有盛誉的大型製药公司的竞争等挑战。值得关注的创新领域包括探索长效疫苗配方、改善免疫反应的新佐剂系统，以及可提供更快生产时间和扩充性的基于 mRNA 的疫苗技术。策略性措施包括联合研发和投资基因工程疫苗，以提供全面的保护，同时最大限度地减少副作用。儘管市场竞争激烈，有GlaxoSmithKline Plc和默克等大公司的存在，但该公司可以透过利用疫苗开发中的人工智慧等技术进步，在不断增长的领域中开拓出一席之地。潜力。

主要市场统计
基准年[2023] 17.3亿美元
预计年份 [2024] 18.7亿美元
预测年份 [2030] 29.9亿美元
复合年增长率（%） 8.11%

市场动态：快速发展的带状疱疹疫苗市场的关键市场洞察

带状疱疹疫苗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性病盛行率增加
    • 世界老年人口的增加
    • 人们对带状疱疹健康风险的认识不断提高，对疫苗接种的兴趣日益浓厚
  • 市场限制因素
    • 疫苗研发需要大量资金
  • 市场机会
    • 带状疱疹疫苗的持续研发计划
    • 全球公共卫生支出大幅增加
  • 市场挑战
    • 与带状疱疹疫苗相关的副作用

波特的五力：驾驭带状疱疹疫苗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解带状疱疹疫苗市场的外部影响

外部宏观环境因素在塑造带状疱疹疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解带状疱疹疫苗市场的竞争格局

带状疱疹疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵带状疱疹疫苗市场供应商的绩效评估

FPNV 定位矩阵是评估带状疱疹疫苗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘带状疱疹疫苗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，带状疱疹疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病增加
      • 世界各地的老年人口正在增加
      • 提高对带状疱疹健康风险的认识并更加关注疫苗接种
    • 抑制因素
      • 疫苗研发需要大量资金
    • 机会
      • 关于带状疱疹疫苗的持续研究和开发工作
      • 全球公共卫生支出大幅增加
    • 任务
      • 与带状疱疹疫苗相关的副作用
  • 市场区隔分析
    • 产品：Shingrix 对于提高安全性日益重要
    • 类型：了解重组带状疱疹疫苗的好处
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章带状疱疹疫苗市场：副产品

  • 天空之星
  • 佐斯塔瓦克斯
  • 定序

第七章带状疱疹疫苗市场：依类型

  • 减毒活疫苗
  • 重组疫苗

第八章带状疱疹疫苗市场：依通路分类

  • 保健中心
  • 药局

第九章美洲带状疱疹疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区带状疱疹疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲带状疱疹疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Dynavax 开始有前途的带状疱疹疫苗 Z-1018 的临床试验
    • 科兴生物将 PROVARIX 疫苗的核准扩大到青少年和成人，以增加公共卫生效益
    • 葛兰素史克 (GSK) 将 Shingrix 疫苗的核准扩大到中国的年轻人，旨在产生更广泛的公共卫生影响
  • 战略分析和建议

公司名单

  • Astellas Pharma Inc.
  • Barinthus Biotherapeutics plc
  • Bavarian Nordic
  • Biogenetech Co., Ltd.
  • CanSino Biologics Inc.
  • CSL Limited
  • Curevo Inc.
  • Daiichi Sankyo Company, Limited
  • Dynavax Technologies Corporation
  • Emergent Biosolutions Inc.
  • GeneOne Life Science, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Jiangsu Recbio Technology Co., Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sinovac Biotech Ltd.
  • SK Chemicals
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • VBI Vaccines Inc.
Product Code: MRR-563BF1FCEEC2

The Shingles Vaccine Market was valued at USD 1.73 billion in 2023, expected to reach USD 1.87 billion in 2024, and is projected to grow at a CAGR of 8.11%, to USD 2.99 billion by 2030.

The global shingles vaccine market is defined by its focus on the prevention of herpes zoster infections, particularly among individuals aged 50 and above. Shingles, caused by the reactivation of the varicella-zoster virus (chickenpox), necessitates vaccination to mitigate severe complications such as postherpetic neuralgia. The market is driven by an increasing aged population, rising awareness about the disease, and advancements in vaccine technology. Key applications include its use in elderly healthcare and immunocompromised patient management. End-user adoption spans across hospitals, clinics, and specialty healthcare centers. Growth factors include robust government initiatives, favorable reimbursement policies, and escalating healthcare expenditure. Opportunities arise from emerging markets with low vaccination rates, opportunities for enhanced vaccine strain targeting, and partnerships for innovative delivery methods. Current recommendations focus on expanding educational programs to boost uptake and employing targeted marketing strategies to reach high-risk demographics. However, limitations include high production costs, stringent regulatory hurdles, and public skepticism over vaccine safety that may hamper rapid market penetration. Additional challenges involve logistical issues in vaccine distribution, impact of vaccine hesitancy, and competition from existing pharmaceutical giants with entrenched healthcare products. Remarkable areas for innovation include research into long-lasting vaccine formulations, novel adjuvant systems to improve immune response, and mRNA-based vaccine technologies, which can offer faster production times and scalability. The strategic movement involves collaborative R&D and investment in genetically engineered vaccines that provide comprehensive coverage with minimal side effects. The market exhibits a competitive nature marked by the presence of major players like GlaxoSmithKline and Merck & Co., but it also presents a dynamic landscape with potential for new entrants who can leverage technological advancements, such as artificial intelligence for vaccine development, to carve out a niche in a growing sector.

KEY MARKET STATISTICS
Base Year [2023] USD 1.73 billion
Estimated Year [2024] USD 1.87 billion
Forecast Year [2030] USD 2.99 billion
CAGR (%) 8.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Shingles Vaccine Market

The Shingles Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases
    • Rising number of geriatric population worldwide
    • Rising awareness about shingles health risks and growing focus on immunization
  • Market Restraints
    • High capital requirements for vaccine development
  • Market Opportunities
    • Ongoing Research & development initiatives on shingles vaccines
    • Significantly increasing public health expenditure worldwide
  • Market Challenges
    • Adverse effects associated with shingles vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Shingles Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Shingles Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Shingles Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Shingles Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Shingles Vaccine Market

A detailed market share analysis in the Shingles Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Shingles Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Shingles Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Shingles Vaccine Market

A strategic analysis of the Shingles Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Shingles Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Barinthus Biotherapeutics plc, Bavarian Nordic, Biogenetech Co., Ltd., CanSino Biologics Inc., CSL Limited, Curevo Inc., Daiichi Sankyo Company, Limited, Dynavax Technologies Corporation, Emergent Biosolutions Inc., GeneOne Life Science, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., JCR Pharmaceuticals Co., Ltd., Jiangsu Recbio Technology Co., Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Sanofi S.A., Sinovac Biotech Ltd., SK Chemicals, Takeda Pharmaceutical Company Limited, Valneva SE, and VBI Vaccines Inc..

Market Segmentation & Coverage

This research report categorizes the Shingles Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across SkyZoster, Zostavax, and Shingrix.
  • Based on Type, market is studied across Live Attenuated Vaccine and Recombinant Vaccine.
  • Based on Distribution Channel, market is studied across Healthcare Centers and Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases
      • 5.1.1.2. Rising number of geriatric population worldwide
      • 5.1.1.3. Rising awareness about shingles health risks and growing focus on immunization
    • 5.1.2. Restraints
      • 5.1.2.1. High capital requirements for vaccine development
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research & development initiatives on shingles vaccines
      • 5.1.3.2. Significantly increasing public health expenditure worldwide
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with shingles vaccines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising significance of Shingrix for higher safety profile
    • 5.2.2. Type: Understanding the benefits of recombinant shingles vaccines
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Shingles Vaccine Market, by Product

  • 6.1. Introduction
  • 6.2. SkyZoster
  • 6.3. Zostavax
  • 6.4. Shingrix

7. Shingles Vaccine Market, by Type

  • 7.1. Introduction
  • 7.2. Live Attenuated Vaccine
  • 7.3. Recombinant Vaccine

8. Shingles Vaccine Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Healthcare Centers
  • 8.3. Pharmacies

9. Americas Shingles Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Shingles Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Shingles Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Dynavax Begins Clinical Trial for Promising Shingles Vaccine, Z-1018
    • 12.3.2. Sinovac Biotech Ltd. Expands PROVARIX Vaccine Approval to Adolescents and Adults, Targeting Increased Public Health Benefits
    • 12.3.3. GSK Expands Shingrix Vaccine Approval to Younger Adults in China, Targets Broader Public Health Impact
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. Barinthus Biotherapeutics plc
  • 3. Bavarian Nordic
  • 4. Biogenetech Co., Ltd.
  • 5. CanSino Biologics Inc.
  • 6. CSL Limited
  • 7. Curevo Inc.
  • 8. Daiichi Sankyo Company, Limited
  • 9. Dynavax Technologies Corporation
  • 10. Emergent Biosolutions Inc.
  • 11. GeneOne Life Science, Inc.
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Inovio Pharmaceuticals, Inc.
  • 15. JCR Pharmaceuticals Co., Ltd.
  • 16. Jiangsu Recbio Technology Co., Ltd.
  • 17. Merck KGaA
  • 18. Moderna, Inc.
  • 19. Pfizer Inc.
  • 20. Sanofi S.A.
  • 21. Sinovac Biotech Ltd.
  • 22. SK Chemicals
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Valneva SE
  • 25. VBI Vaccines Inc.

LIST OF FIGURES

  • FIGURE 1. SHINGLES VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. SHINGLES VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SHINGLES VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SHINGLES VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SKYZOSTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTAVAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SHINGRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HEALTHCARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2023